What is a blood transfusion? A blood transfusion involves receiving donated blood or blood parts into your body through one of your blood vessels. A needle is put into a vein, often in the arm. The ...
Aardvark Therapeutics filed for an IPO Thursday night, making it the sixth biotech in line this year for a potential listing … ...
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...
AbbVie has completed the acquisition of Nimble Therapeutics. Credit: © AbbVie Inc. All rights reserved. AbbVie and Neomorph are forming a partnership and option-to ...
Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. Patents protecting ...
As the first major drug industry conference each year, the J.P. Morgan Healthcare Conference is regularly described as a barometer of expectations for the year ahead. Rather than ebullient, the ...
NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback